For the complete report, get in touch with us at : info@netscribes.com The report begins with the market overview section which provides an insight into the global market, highlighting the market size and growth. It then moves onto the Indian market, with a focus on market size and growth. It also provides import and export figures of cancer drugs in India in terms of value. Regional break-up of the imports and exports have been included. An analysis of the drivers explains the factors for growth of the industry including increasing cancer cases, changes in the treatment scenario, development of alternative cancer therapies, increasing FDI and increase in the number of cancer health insurances. The key challenges include increased competition, drug patent problems and drug portfolio management problems. The government initiatives section highlights the PPP R&D projects started in the country. It also analyses the various initiatives undertaken to reduce prices of cancer drugs, the various cancer control programmes implemented and the changes in the custom duty structure. A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals. The competition section gives overview of pharmaceutical companies in the country operating in the cardiovascular pharmaceutical industry. The report highlights features of the major players operating in the market in detail. It includes elaborate profile of the major players in the market along with their financial analysis. It also incorporates the recent developments in the Oncology Pharmaceutical industry.

1. Oncology Pharmaceuticals Market India
Oncology Pharmaceuticals Market‐India
August 2011
Oncology Pharmaceuticals Market in India
Oncology Pharmaceuticals Market in India
April 2012 1

2. Executive Summary
 Oncology pharmaceuticals market in India is valued at INR x bn in 20—
Market  Fourth largest in volume, eighth largest in value in the world market
 Market is expected to grow at a CAGR of y% from20‐‐‐‐‐
Drivers:
Di Challenges:
Ch ll
 Increasing number of cancer cases  Increased competition
Drivers and  Changes in the treatment scenario  Drug patents problem
Challenges  Development of alternative cancer  Drug Portfolio management
therapies
p
 Increase in cancer insurances
 Increase in FDI
 Reforms in tax structure
Government  Reduction in drug prices
gp
Initiatives  Public –Private Partnership (PPP) programmes
 Drug control programmes
 Phases of clinical trial
Drug regulation
g g  Approval and licensing of drugs
Approval and licensing of drugs
and patents  Patents
 Highly fragmented market with large number of players
 Major public players in the market include Company A,Company B, Company C, Company D,
Competition
p Company E, Company F, Company G, Company H, Company I, Company J
Company E Company F Company G Company H Company I Company J
 Major private companies include Company K, Company L, Company M
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 2

3. •Market Overview
•Market Overview
•Drivers & Challenges
•Government Initiatives
•Government Initiatives
•Market Value Chain, Regulation and
Patents
•Competition
•Strategic Recommendation
St t i R d ti
•Appendix
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2011.PPT
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 3

4. Indian oncology pharma market has grown enormously over
the last few years
Indian market‐overview Market size
INR unit
•Fourth largest in volume, eighth largest in
50
value in the world market g
40 m%
%
•Expected to reach INR y bn in 20‐‐ f
30 e
•Cancer is the second largest cause of death in d
20 b c
a
the country 10
•According to the National Cancer Registry
•According to the National Cancer Registry 0
Program (NCRP) there are z mn cancer 20‐‐ 20‐‐ 20‐‐e 20‐‐e 20‐‐e 20‐‐e 20‐‐e
patients at any point of time
•There occurs X cancer related deaths each Increase in Cancer Cases
year In ‘000
•Oral and lung cancer are the most common in 1,200 n%
males, while in females, cervical, followed by 1,000
breast and ovarian cancer are the most 800
common 600 y
x
400
•Availibilty of xx oncologists per yy people in
200
India 0
20
20‐‐ 20 e
20‐‐e
Source:
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 4

5. A huge volume of cancer drugs is exported to many
countries…
Exports of Oncological Pharmaceuticals Total Exports
• Highly fragmented market with many domestic INR units
manufacturers lead to huge volume of exports 4,000 e5
• India currently exports to more than 115 countries P% e4
3,000
• Between 20‐‐ ‐ 20‐‐ and 20‐‐ ‐ 20‐‐ the value of export e3
2,000
of oncology pharmaceuticals rose by m% e2
1,000 e1
• Country A accounted for the highest exports in 20‐‐ ‐
20‐‐ while Country B ranked highest in 20‐‐ ‐ 20‐‐ 0
20–to 20‐‐ 20– to 20‐‐ 20– to 20‐‐ 20– to 20‐‐ 20– to 20‐‐
Exports – Region wise (20‐‐ ‐ 20‐‐)
p g ( ) Exports – Region wise (20‐‐ ‐ 20‐‐)
p g ( )
Country A
A2%
A1% Country B
G2%
G1% Country C
Country C
Country D
B2%
E1% Country E
B1% E2%
D1% Country F
C1% D2%
Country G F2%
%
Source: Ministry of Commerce: Export‐Import Data Bank Note: All figures are for financial year
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 5

6. Drivers & Challenges ‐ Summary
Challenges
Drivers Increased competition
Increasing number of cancer cases
Drug patent problems
Changes in the treatment scenario
Drug portfolio management
Development of alternative cancer
D l t f lt ti
therapies Lack of affordability
Increase in cancer insurances
Increase in the amount of FDI
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 6

7. Government initiatives
Reforms in tax structure Public-Private-partnership
(PPP) projects
Government
Initiative
Cancer control programmes Reduction in drug prices
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 7

8. Public: Domestic Company – Company A (1/3)
Company Information Offices and Centres – India
X Road
Corporate Address
Bangalore
Tel No.
No +91 xx xxxxx xxxxx
Fax No. +91 xx xxxxx xxxxx
Website www.ppp.com
Year of
19--
Incorporation
Ticker Symbol xxxxxx
Stock Exchange NNN
Products and Services
Products and Services City A
City A
Head Office
Category Products/Services
CVD, oncology, CNS, respiratory, Key People
Pharmaceutical dermatology, orthopedics, nutritional,
urology, anti‐infectives
l ii f i Name Designation
Infectious diseases, metabolic diseases, Person M Founder
Molecule
inflammatory/respiratory diseases, and Person N CFO
Development
oncology
Person O Head
Person Q President
Source:
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 8

9. Public: Domestic Company – Company B (2/3)
Financial Snapshot
i i lS h Key Ratios
K i
Revenue Profit Particulars y‐o‐y change 20‐‐ 20‐‐ 20‐‐ 20‐‐
INR mn Revenue INR mn Profitability Ratios
q r Profit / Loss
10,000 p Operating Margin
s Net Margin
n Profit Before Tax Margin
5,000
m n o p 0 Return on Equity
t Return on Capital Employed
0 ‐m Return on Working Capital
20‐‐ 20‐‐ 20‐‐ 20‐‐ Return on Assets
Financial Summary Return on Fixed Assets
Cost Ratios
• The company incurred a net loss of INR xx mn in FY 20‐‐, as Operating costs (% of Sales)
compared to net profit of INR yy mn in FY 20‐‐ Administration costs (% of
• The company reported total income of INR xx bn in FY 20‐‐, Sales)
registering an increase of yy per cent over FY 20‐‐
registering an increase of yy per cent over FY 20 Interest costs (% of Sales)
Interest costs (% of Sales)
Liquidity Ratios
• The company earned an operating margin of x per cent in FY 20‐‐ a
Current Ratio
decrease of y percentage points over FY 20‐‐
Cash Ratio
• The company reported debt to equity ratio of x in FY 20‐‐, an Leverage Ratios
increase of y per cent over FY 20‐‐ Debt to Equity Ratio
Financial Summary
Financial Summary Debt to Capital Ratio
b i l i
Interest Coverage Ratio
Indicators Present Value Efficiency Ratios
Market Capitalization (INR) X units Fixed Asset Turnover
Total Enterprise Value (INR) Y units Asset Turnover
EPS (INR) Z units Current Asset Turnover
Working Capital Turnover
PE Ratio (Absolute) A
Capital Employed Turnover
Source: Improved Decline
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 9

10. Public: Domestic Company – Company C (3/3)
Key Business Segments Key Geographic Segments
m n o x y z
x
x x
x x
x x y
x y y
y
y y y y z z z z
z z z z
20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐ 20‐‐
Key Recent Developments
Description
i i News
• Company A is an integrated research based company that produces a wide range of generic medicines
Overview
• Serves customers in over 100 countries with manufacturing facilities in several countries
Oncology Pharmaceuticals • Products include include Product 1 and Product 2
• Is making consistent effort for continual improvement in rural areas with respect to accessibility of
Key Initiatives medicines
Source:
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 10

11. Thank you for the attention
The Oncology Pharmaceuticals Market – India report is part of Netscribes’ Healthcare Industry
Series.
For more detailed information or customized research requirements please contact:
Contact Number: +91 33 4064 6214
C N b 91 33 4064 6214
E‐Mail: sales@netscribes.com
Netscribes (India) Pvt. Ltd. is dedicated to disseminating information and providing quick insights on hot industries in India and other
Netscribes (India) Pvt Ltd is dedicated to disseminating information and providing quick insights on “hot” industries in India and other
emerging markets. Track our new releases and major updates in these industries on
About Netscribes
Netscribes is a knowledge‐consulting and solutions firm with clientele across the globe. The company’s expertise spans areas of investment &
g g f g p y p p f
business research, business & corporate intelligence, content‐management services, and knowledge‐software services. At its core lies a true
value proposition that draws upon a vast knowledge base. Netscribes is a one‐stop shop designed to fulfil clients’ profitability and growth
objectives.
Disclaimer: This report is published for general information only. Although high standards have been used the preparation, Netscribes (India)
Disclaimer: This report is published for general information only Although high standards have been used the preparation Netscribes (India)
Pvt. Ltd. or “Netscribes” is not responsible for any loss or damage arising from use of this document. This document is the sole property of
Netscribes (India) Pvt. Ltd. and prior permission is required for guidelines on reproduction.
ONCOLOGY PHARMACEUTICALS MARKET IN INDIA 2012.PPT 11